Tags

Type your tag names separated by a space and hit enter

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
Dement Geriatr Cogn Disord 2005; 19(2-3):164-70DG

Abstract

The intra vitam diagnosis of dementia with Lewy bodies (DLB) is still based on clinical grounds. So far no technical investigations have been available to support this diagnosis. As for tau protein and beta-amyloid(1-42) (Abeta42), promising results for the diagnosis of Alzheimer's disease (AD) have been reported; we evaluated these markers and S-100B protein in cerebrospinal fluid (CSF), using a set of commercially available assays, of 71 patients with DLB, 67 patients with AD and 41 nondemented controls (NDC) for their differential diagnostic relevance. Patients with DLB showed significantly lower tau protein values compared to AD but with a high overlap of values. More prominent differences were observed in the comparison of DLB patients with all three clinical core features and AD patients. Abeta42 levels were decreased in the DLB and AD groups versus NDC, without significant subgroup differences. S-100B levels were not significantly different between the groups. Tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited especially due to mixed pathology. We conclude that more specific markers have to be established for the differentiation of these diseases.

Authors+Show Affiliations

Department of Neurology, Georg August University Göttingen, Göttingen, Germany. bmollenhauer@med.uni-goettingen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15637452

Citation

Mollenhauer, Brit, et al. "Tau Protein, Abeta42 and S-100B Protein in Cerebrospinal Fluid of Patients With Dementia With Lewy Bodies." Dementia and Geriatric Cognitive Disorders, vol. 19, no. 2-3, 2005, pp. 164-70.
Mollenhauer B, Cepek L, Bibl M, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005;19(2-3):164-70.
Mollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz-Schaeffer, W. J., Ciesielczyk, B., ... Otto, M. (2005). Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders, 19(2-3), pp. 164-70.
Mollenhauer B, et al. Tau Protein, Abeta42 and S-100B Protein in Cerebrospinal Fluid of Patients With Dementia With Lewy Bodies. Dement Geriatr Cogn Disord. 2005;19(2-3):164-70. PubMed PMID: 15637452.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. AU - Mollenhauer,Brit, AU - Cepek,Lukas, AU - Bibl,Mirko, AU - Wiltfang,Jens, AU - Schulz-Schaeffer,Walter J, AU - Ciesielczyk,Barbara, AU - Neumann,Manuela, AU - Steinacker,Petra, AU - Kretzschmar,Hans A, AU - Poser,Sigrid, AU - Trenkwalder,Claudia, AU - Otto,Markus, Y1 - 2005/01/05/ PY - 2004/06/18/accepted PY - 2005/1/8/pubmed PY - 2005/6/25/medline PY - 2005/1/8/entrez SP - 164 EP - 70 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 19 IS - 2-3 N2 - The intra vitam diagnosis of dementia with Lewy bodies (DLB) is still based on clinical grounds. So far no technical investigations have been available to support this diagnosis. As for tau protein and beta-amyloid(1-42) (Abeta42), promising results for the diagnosis of Alzheimer's disease (AD) have been reported; we evaluated these markers and S-100B protein in cerebrospinal fluid (CSF), using a set of commercially available assays, of 71 patients with DLB, 67 patients with AD and 41 nondemented controls (NDC) for their differential diagnostic relevance. Patients with DLB showed significantly lower tau protein values compared to AD but with a high overlap of values. More prominent differences were observed in the comparison of DLB patients with all three clinical core features and AD patients. Abeta42 levels were decreased in the DLB and AD groups versus NDC, without significant subgroup differences. S-100B levels were not significantly different between the groups. Tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited especially due to mixed pathology. We conclude that more specific markers have to be established for the differentiation of these diseases. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/15637452/Tau_protein_Abeta42_and_S_100B_protein_in_cerebrospinal_fluid_of_patients_with_dementia_with_Lewy_bodies_ L2 - https://www.karger.com?DOI=10.1159/000083178 DB - PRIME DP - Unbound Medicine ER -